BRCA1 Mutations in Ashkenazi Jews and Genetic Markers
Author Information
Author(s): Pereira Lutécia H Mateus, Pineda Marbin A, Rowe William H, Fonseca Libia R, Greene Mark H, Offit Kenneth, Ellis Nathan A, Zhang Jinghui, Collins Andrew, Struewing Jeffery P
Primary Institution: National Cancer Institute
Hypothesis
Can we identify the 185delAG mutation in a case-control association study using anonymous genetic markers?
Conclusion
It would have been difficult to map BRCA1 in an Ashkenazi case-control association study using anonymous markers linked to the founder mutations.
Supporting Evidence
- The 185delAG mutation is present in approximately 1% of the general Ashkenazi population and 4% of Ashkenazi breast cancer cases.
- BRCA1 is characterized by very high linkage disequilibrium in all populations spanning several hundred kilobases.
- The study found that the required sample size to detect the 185delAG mutation would be at least 25 times larger if the mutation was not tested directly.
Takeaway
The study looked at genetic markers in Ashkenazi Jews to see if they could find a specific mutation linked to breast cancer, but it turns out it would be really hard to find it using common markers.
Methodology
The study analyzed linkage disequilibrium patterns at the BRCA1 locus using 114 SNPs across five population groups.
Limitations
The study's findings are limited by the rarity of the founder mutations and the low correlation coefficients with common SNPs.
Participant Demographics
The study included 289 unrelated reference subjects from five population groups: 85 Ashkenazi Jews, 60 European-Americans, and 48 each from African-Americans, Chinese-Americans, and Mexican-Americans.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website